Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis.

Dimitriou, Florentia; Staeger, Ramon; Ak, Melike; Maissen, Matias; Kudura, Ken; Barysch, Marjam J; Levesque, Mitchell P; Cheng, Phil F; Dummer, Reinhard; Mangana, Joanna

Dimitriou, Florentia; Staeger, Ramon; Ak, Melike; Maissen, Matias; Kudura, Ken; Barysch, Marjam J; Levesque, Mitchell P; Cheng, Phil F; Dummer, Reinhard; Mangana, Joanna.

Afiliação

Dimitriou F; Department of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland.
Staeger R; Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.
Ak M; Department of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland.
Maissen M; Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.
Kudura K; Department of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland.
Barysch MJ; Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.
Levesque MP; Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.
Cheng PF; Department of Nuclear Medicine, University Hospital Zurich, 8091 Zurich, Switzerland.
Dummer R; Department of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland.
Mangana J; Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.

Cancers (Basel) ; 13(12)2021 Jun 11.

Article em En | MEDLINE | ID: mdl-34208218

Palavras-chave

immune-related adverse events; immunotherapy; infliximab; melanoma; tocilizumab

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suíça País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google